IVA vs MENS: fair value comparison
Inventiva S.A. and Jyong Biotech Ltd. · Updated 2026-10-19
IVA reports in EUR, so no same-currency fair-value verdict is published for it. MENS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IVA currently ranks higher by quality score.
| IVA | MENS | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $3.46 | $1.84 |
| 12-month range | $2.87–$7.15 | $1.46–$60.80 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #294 of 301 Healthcare | #296 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Contracting | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: IVA fair value analysis · MENS fair value analysis